These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

728 related articles for article (PubMed ID: 32213052)

  • 1. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis.
    Ochsenkühn T; Tillack C; Szokodi D; Janelidze S; Schnitzler F
    United European Gastroenterol J; 2020 Feb; 8(1):91-98. PubMed ID: 32213052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sands BE; Sandborn WJ; Panaccione R; O'Brien CD; Zhang H; Johanns J; Adedokun OJ; Li K; Peyrin-Biroulet L; Van Assche G; Danese S; Targan S; Abreu MT; Hisamatsu T; Szapary P; Marano C;
    N Engl J Med; 2019 Sep; 381(13):1201-1214. PubMed ID: 31553833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis.
    Li K; Marano C; Zhang H; Yang F; Sandborn WJ; Sands BE; Feagan BG; Rubin DT; Peyrin-Biroulet L; Friedman JR; De Hertogh G
    Gastroenterology; 2020 Dec; 159(6):2052-2064. PubMed ID: 32853634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis.
    Hoffmann P; Wehling C; Krisam J; Pfeiffenberger J; Belling N; Gauss A
    World J Gastroenterol; 2019 Apr; 25(13):1603-1617. PubMed ID: 30983820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real World Experience With Ustekinumab in Children and Young Adults at a Tertiary Care Pediatric Inflammatory Bowel Disease Center.
    Dayan JR; Dolinger M; Benkov K; Dunkin D; Jossen J; Lai J; Phan BL; Pittman N; Dubinsky MC
    J Pediatr Gastroenterol Nutr; 2019 Jul; 69(1):61-67. PubMed ID: 31058718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis.
    Sandborn WJ; Baert F; Danese S; Krznarić Ž; Kobayashi T; Yao X; Chen J; Rosario M; Bhatia S; Kisfalvi K; D'Haens G; Vermeire S
    Gastroenterology; 2020 Feb; 158(3):562-572.e12. PubMed ID: 31470005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis.
    Adedokun OJ; Xu Z; Marano C; O'Brien C; Szapary P; Zhang H; Johanns J; Leong RW; Hisamatsu T; Van Assche G; Danese S; Abreu MT; Sands BE; Sandborn WJ
    Clin Gastroenterol Hepatol; 2020 Sep; 18(10):2244-2255.e9. PubMed ID: 31816446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
    Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
    Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study.
    Bar-Gil Shitrit A; Ben-Ya'acov A; Siterman M; Waterman M; Hirsh A; Schwartz D; Zittan E; Adler Y; Koslowsky B; Avni-Biron I; Chowers Y; Ron Y; Israeli E; Ungar B; Yanai H; Maharshak N; Ben-Horin S; Eliakim R; Dotan I; Goldin E; Kopylov U
    United European Gastroenterol J; 2020 May; 8(4):418-424. PubMed ID: 32213026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus.
    Yamamoto S; Nakase H; Matsuura M; Honzawa Y; Masuda S; Inui K; Chiba T
    J Gastroenterol Hepatol; 2010 May; 25(5):886-91. PubMed ID: 20546441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Ustekinumab in Adults With Moderately to Severely Active Ulcerative Colitis.
    Xu Y; Hu C; Chen Y; Miao X; Adedokun OJ; Xu Z; Sharma A; Zhou H
    J Clin Pharmacol; 2020 Jul; 60(7):889-902. PubMed ID: 32026499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    Sands BE; Peyrin-Biroulet L; Loftus EV; Danese S; Colombel JF; Törüner M; Jonaitis L; Abhyankar B; Chen J; Rogers R; Lirio RA; Bornstein JD; Schreiber S;
    N Engl J Med; 2019 Sep; 381(13):1215-1226. PubMed ID: 31553834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of cyclosporin induction and ustekinumab maintenance combination therapy in patients with steroid-refractory acute severe ulcerative colitis.
    Vitali F; Rath T; Klenske E; Vögele AL; Ganzleben I; Zundler S; Strobel D; Geppert C; Hartmann A; Neurath MF; Atreya R
    Therap Adv Gastroenterol; 2024; 17():17562848231218555. PubMed ID: 38164363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease.
    Hoffmann P; Krisam J; Wehling C; Kloeters-Plachky P; Leopold Y; Belling N; Gauss A
    World J Gastroenterol; 2019 Aug; 25(31):4481-4492. PubMed ID: 31496626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study.
    Amiot A; Filippi J; Abitbol V; Cadiot G; Laharie D; Serrero M; Altwegg R; Bouhnik Y; Peyrin-Biroulet L; Gilletta C; Roblin X; Pineton de Chambrun G; Vuitton L; Bourrier A; Nancey S; Gornet JM; Nahon S; Bouguen G; Viennot S; Pariente B; Fumery M;
    Aliment Pharmacol Ther; 2020 Jun; 51(11):1039-1046. PubMed ID: 32291786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis.
    Hussey M; Mc Garrigle R; Kennedy U; Holleran G; Kevans D; Ryan B; Breslin N; Mahmud N; McNamara D
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):217-21. PubMed ID: 26587866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
    Peyrin-Biroulet L; Loftus EV; Colombel JF; Danese S; Rogers R; Bornstein JD; Chen J; Schreiber S; Sands BE; Lirio RA
    Gastroenterology; 2021 Oct; 161(4):1156-1167.e3. PubMed ID: 34144047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry.
    Chaparro M; Garre A; Iborra M; Sierra-Ausín M; Barreiro-de Acosta M; Fernández-Clotet A; de Castro L; Boscá-Watts M; Casanova MJ; López-García A; Lorente R; Rodríguez C; Carbajo AY; Arroyo MT; Gutiérrez A; Hinojosa J; Martínez-Pérez T; Villoria A; Bermejo F; Busquets D; Camps B; Cañete F; Manceñido N; Monfort D; Navarro-Llavat M; Pérez-Calle JL; Ramos L; Rivero M; Angueira T; Camo Monterde P; Carpio D; García-de-la-Filia I; González-Muñoza C; Hernández L; Huguet JM; Morales VJ; Sicilia B; Vega P; Vera I; Zabana Y; Nos P; Suárez Álvarez P; Calviño-Suárez C; Ricart E; Hernández V; Mínguez M; Márquez L; Hervías Cruz D; Rubio Iturria S; Barrio J; Gargallo-Puyuelo C; Francés R; Hinojosa E; Del Moral M; Calvet X; Algaba A; Aldeguer X; Guardiola J; Mañosa M; Pajares R; Piqueras M; García-Bosch O; López Serrano P; Castro B; Lucendo AJ; Montoro M; Castro Ortiz E; Mesonero F; García-Planella E; Fuentes DA; Bort I; Delgado-Guillena P; Arias L; Iglesias A; Calvo M; Esteve M; Domènech E; Gisbert JP
    J Crohns Colitis; 2021 Nov; 15(11):1846-1851. PubMed ID: 33860795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.